Investigational drug · Phase 2
EDI048
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cryptosporidiosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "EDI048"
First trial start
2025
Dec 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EDI048", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cryptosporidiosis
Largest trials
Live from ClinicalTrials.gov: studies naming "EDI048" as an intervention, largest first.
- First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy VolunteersPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT05275855 · 110 participants · Start Apr 29, 2022 · Primary completion Dec 18, 2024
Drug: EDI048 · For: Healthy Volunteers
Sites: Mere Way, United Kingdom
Novartis PharmaceuticalsNovartis (NVS)
NCT07249463 · 80 participants (planned) · Start Dec 8, 2025 · Primary completion Mar 23, 2027
Drug: Cryptosporidium parvum oocysts (ABO809); EDI048 · For: Cryptosporidiosis
Sites: Baltimore, Maryland; Cincinnati, Ohio
Newest research
PubMed records naming it or its code names, newest first.
- A First-in-Human Phase 1 Clinical Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of EDI048, a Novel Promising Agent to Treat Enteric Cryptosporidiosis.
Jain M, Stevenson K, Cheblal A, et al. · J Infect Dis 2026
- Cryptosporidium PI(4)K inhibitor EDI048 is a gut-restricted parasiticidal agent to treat paediatric enteric cryptosporidiosis.
Manjunatha UH, Lakshminarayana SB, Jumani RS, et al. · Nat Microbiol 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.